SEC Info - American Bio Medica Corp - ‘NT 10-K’ for 12/31/19

SEC Info℠

Home

Help

Please Sign In

American Bio Medica Corp – ‘NT 10-K’ for 12/31/19

On: Monday, 3/30/20, at 3:24pm ET · Effective: 3/30/20 · For: 12/31/19 · Accession #: 1654954-20-3473 · File #: 0-28666

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 3/30/20  American Bio Medica Corp          NT 10-K    12/31/19    1:58K                                    Blueprint/FA

Notice of a Late Filing of a Form 10-K — Rule 12b-25
Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: NT 10-K     Notice of a Late Filing of a Form 10-K              HTML     29K

This is an HTML Document rendered as filed. [ Alternative Formats ]

C: C:

abmc_nt10k

	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549



	FORM 12b-25		SEC FILE NUMBER
	FORM 12b-25		0-28666

			CUSIP NUMBER
	NOTIFICATION OF LATE FILING		024600

(Check one):

☑

Form 10-K

☐

Form 20-F

☐

Form 11-K

☐

Form 10-Q

☐

Form 10-D

☐

Form N-SAR

☐

Form N-CSR

For Period Ended: December 31, 2019

☐

Transition Report on Form 10-K

☐

Transition Report on Form 20-F

☐

Transition Report on Form 11-K

☐

Transition Report on Form 10-Q

☐

Transition Report on Form N-SAR

For the Transition Period Ended:

Nothing in this form shall be construed to imply that the Commission has verified any information contained herein.

If the notification relates to a portion of the filing checked above, identify the Item(s) to which the notification relates: Not Applicable

PART I - REGISTRANT INFORMATION

American Bio Medica Corporation

Full name of registrant

Not Applicable

Former Name if Applicable

122 Smith Road

Address of Pincipal Eecutive Ofice (Sreet and Number)

Kinderhook, New York 12106

City, Sate and Zip Code

PART II - RULES 12b-25(b) AND (c)

If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed. (Check box if appropriate)

	(a)	The reason described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense

☒	(b)	The subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, Form 11-K, Form N-SAR or Form N-CSR, or portion thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report or transition report on Form 10-Q or subject distribution report on Form 10-D, or portion thereof, will be filed on or before the fifth calendar day following the prescribed due date; and

	(c)	The accountant’s statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.

PART III - NARRATIVE

State below in reasonable detail the reasons why Forms 10-K, 20-F, 11-K, 10-Q, 10-D, N-SAR, N-CSR or the transition report or portion thereof, could not be filed within the prescribed time period. (Attach extra Sheets if Needed.)

The registrant is not able to timely file its requisite annual report on Form 10-K for the fiscal year ended December 31, 2019 by the prescribed due date without incurring undue hardship and expense. The registrant, its consultants and advisors are being impacted by government imposed restrictions due to the outbreak of corornavirus (COVID-19), which has contributed to the delay in compiling and completing the registrant’s annual report. The registrant reasonably believes that it will be able to complete and file its Form 10-K for December 31, 2019 within the prescribed, extended extension period, on or prior to May 14, 2020.

PART IV - OTHER INFORMATION

(1)	Name and telephone number of person to contact in regard to this notification

	Melissa A. Waterhouse	(518)	758-8158
	(Name)	(Area Code)	(Telephone Number)

(2)	Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed? If answer is no, identify report(s).
Yes				☒	No	☐


(3)	Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof?
Yes				☐	No	☒

	If so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made.

AMERICAN BIO MEDICA CORPORATION

(Name of Registrant as Specified in Charter)

Has caused this notification to be signed on its behalf by the undersigned hereunto duly authorized.


Date: March 30, 2020	By:	/s/ Melissa A. Waterhouse
		Melissa A. Waterhouse
		Chief Executive Officer / Pricipal Financial Officer

Dates Referenced Herein and Documents Incorporated by Reference

This ‘NT 10-K’ Filing	Date	Other Filings

	5/14/20
Filed on / Effective on:	3/30/20
For Period end:	12/31/19	5
		List all Filings

↑Top

Filing Submission 0001654954-20-003473 – Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)

American Bio Medica Corp – ‘NT 10-K’ for 12/31/19

On: Monday, 3/30/20, at 3:24pm ET · Effective: 3/30/20 · For: 12/31/19 · Accession #: 1654954-20-3473 · File #: 0-28666

Previous ‘NT 10-K’: ‘NT 10-K’ on 3/29/19 for 12/31/18 · Next: ‘NT 10-K/A’ on 5/14/20 for 12/31/19 · Latest: ‘NT 10-K’ on 3/31/22 for 12/31/21

Notice of a Late Filing of a Form 10-K — Rule 12b-25Filing Table of Contents

This is an HTML Document rendered as filed. [ Alternative Formats ]

Dates Referenced Herein and Documents Incorporated by Reference

Notice of a Late Filing of a Form 10-K — Rule 12b-25
Filing Table of Contents